Evidence map›Paper›PMID 36936914›Full record

Trial reportFrontiers in immunology2023

Use of

Alexander Bertuccioli, Marco Gervasi, Giosuè Annibalini, Beatrice Binato, Fabrizio Perroni, Marco B L Rocchi, Davide Sisti, Stefano Amatori

Open access · goldFull text readRandomized Controlled Trial
In one paragraph

Trial report in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Efficacy ofMicroorganisms · 2024
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alexander BertuccioliDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Marco GervasiDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Giosuè AnnibaliniDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Beatrice BinatoDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Fabrizio PerroniDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Marco B L RocchiDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Davide SistiDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Stefano AmatoriDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
University of Urbino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Upper respiratory tract infections (URTI) are the most common illnesses affecting athletes, causing absences from training and competition. Salivary immunoglobulin A (sIgA) is the main immune factor in saliva, and a consistent association between low concentrations of sIgA and an increased incidence of URTIs has been reported. The oral probiotic Methods: Active young students were randomised into a treated group ( Results: Twenty (M = 14, F = 6) young subjects (23.5 ± 2.3 years old) participated in the study. The total accumulated training load (sRPE) in the supplementation period was similar in the two groups (treated: 4345 ± 3441 AU; control: 4969 ± 4165 AU; p > 0.05). Considering both sIgA level and secretion rate, significant time (F Conclusion: This study demonstrates that relatively short-term

Indexed as

Streptococcus salivariusAdultDouble-Blind MethodHumansImmunityImmunoglobulin A, SecretorySalivaYoung AdultImmunoglobulin A, SecretorybacteriocinHITIgAStreptococcus salivarius K12URTI

Identifiers

PMID36936914
PMCPMC10019894
OpenAlexW4322763772

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read18
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.